-
Something wrong with this record ?
Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry
J. Blatný, P. Mathew, P. Monagle, P. Ovesna, V. Fiamoli,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Child MeSH
- Factor VIIa adverse effects therapeutic use MeSH
- Infant MeSH
- Hemorrhage drug therapy MeSH
- Humans MeSH
- Adolescent MeSH
- Child, Preschool MeSH
- Registries MeSH
- Recombinant Proteins adverse effects therapeutic use MeSH
- Retrospective Studies MeSH
- Check Tag
- Child MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Male MeSH
- Child, Preschool MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We evaluated efficacy and safety of recombinant activated factor VII (rFVIIa) in nonhemophilia children with life-threatening or severe bleeding. Using data from the SeveNBleeP registry, we analyzed demographic, clinical, laboratory, and treatment data for children who received rFVIIa to treat severe hemorrhage. The SeveNBleeP registry was international registry formed in 2005, to collect information on the use of rFVIIa in the off-label setting of severe bleeding in nonhemophilia patients. There were 191 patient records entered into this registry, of which 164 were validated. Of the 164 records, in 137 patient records, rFVIIa was used for treatment of bleeding episodes. Of these 137 treatment episodes, 42 were in neonates and infants under 1 year of age. Use of rFVIIa significantly improved laboratory parameters (prothrombin time, international normalized ratio, activated partial thromboplastin time, hematocrit), reduced estimated blood loss, and reduced requirements for blood products (packed red blood cells and fresh frozen plasma) in those more than 1 year of age. There was no significant reduction in requirements for blood products after rFVIIa administration in the neonates and infants, but there was a trend to lower frequency of FFP use after rFVIIa administration. There was one thromboembolic event in an infant that was related to administration of rFVIIa. No other serious adverse events were reported that were related to administration of rFVIIa. In nonhemophilia-associated bleeding in children, rFVIIa appears to be safe and efficacious in reducing estimated blood loss in children over 1 year of age, although its effectiveness in infants below 1 year of age was less clear.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15032075
- 003
- CZ-PrNML
- 005
- 20151008115537.0
- 007
- ta
- 008
- 151005s2014 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MBC.0000000000000036 $2 doi
- 035 __
- $a (PubMed)24389586
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Blatný, Jan $u aDepartment of Paediatric Haematology, Children's University Hospital Brno, Brno, Czech Republic bDepartment of Pediatrics, University of New Mexico, Albuquerque, New Mexico, USA cDepartment of Pediatrics, Royal Children's Hospital, University of Melbourne, Melbourne, Australia dInstitute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.
- 245 10
- $a Safety and efficacy of recombinant activated factor VII in nonhemophilia children with severe or life-threatening bleeding: a report from the SeveNBleeP registry / $c J. Blatný, P. Mathew, P. Monagle, P. Ovesna, V. Fiamoli,
- 520 9_
- $a We evaluated efficacy and safety of recombinant activated factor VII (rFVIIa) in nonhemophilia children with life-threatening or severe bleeding. Using data from the SeveNBleeP registry, we analyzed demographic, clinical, laboratory, and treatment data for children who received rFVIIa to treat severe hemorrhage. The SeveNBleeP registry was international registry formed in 2005, to collect information on the use of rFVIIa in the off-label setting of severe bleeding in nonhemophilia patients. There were 191 patient records entered into this registry, of which 164 were validated. Of the 164 records, in 137 patient records, rFVIIa was used for treatment of bleeding episodes. Of these 137 treatment episodes, 42 were in neonates and infants under 1 year of age. Use of rFVIIa significantly improved laboratory parameters (prothrombin time, international normalized ratio, activated partial thromboplastin time, hematocrit), reduced estimated blood loss, and reduced requirements for blood products (packed red blood cells and fresh frozen plasma) in those more than 1 year of age. There was no significant reduction in requirements for blood products after rFVIIa administration in the neonates and infants, but there was a trend to lower frequency of FFP use after rFVIIa administration. There was one thromboembolic event in an infant that was related to administration of rFVIIa. No other serious adverse events were reported that were related to administration of rFVIIa. In nonhemophilia-associated bleeding in children, rFVIIa appears to be safe and efficacious in reducing estimated blood loss in children over 1 year of age, although its effectiveness in infants below 1 year of age was less clear.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a faktor VIIa $x škodlivé účinky $x terapeutické užití $7 D015942
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a krvácení $x farmakoterapie $7 D006470
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a rekombinantní proteiny $x škodlivé účinky $x terapeutické užití $7 D011994
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Mathew, Prasad
- 700 1_
- $a Monagle, Paul
- 700 1_
- $a Ovesna, Petra
- 700 1_
- $a Fiamoli, Veronika
- 773 0_
- $w MED00009346 $t Blood coagulation & fibrinolysis an international journal in haemostasis and thrombosis $x 1473-5733 $g Roč. 25, č. 4 (2014), s. 326-32
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24389586 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151008115723 $b ABA008
- 999 __
- $a ok $b bmc $g 1092951 $s 915201
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 25 $c 4 $d 326-32 $i 1473-5733 $m Blood coagulation & fibrinolysis $n Blood Coagul Fibrinolysis $x MED00009346
- LZP __
- $a Pubmed-20151005